The purpose of this core resource laboratory is to provide ongoing support for the clinical immunotherapy program in the Surgery Branch of the National Cancer Institute. The laboratory is managed by two co-investigators, Drs. Mark Dudley and John Wunderlich, and each investigator has submitted the same annual report. The major effort in the laboratory is producing, ex vivo, large numbers of human anticancer T lymphocytes that are used in adoptive immunotherapy for patients enrolled in Surgery Branch clinical trials. All of the patients have metastatic cancer, primarily melanoma but also human papilloma-induced cancers, synovial sarcoma, lymphoma, and others. Commonly, one to one hundred billion cells are used for each treatment. The anticancer cells are generated in vitro from each patients lymphocytes. The lymphocytes have natural anticancer activity, or anticancer activity induced or enhanced by genetic modification of the cells in vitro. One hundred fourteen patients with metastatic cancer have been treated with anticancer lymphocytes during FY13 through August 14. During part or all of this same period of time, fifteen different clinical trials devoted to these therapies have been active and supported by the core laboratory. The core laboratory has also carried out research activities to improve its services. Thus, efforts have continued 1) to simplify the cell production methodology and make the process more cost effective, 2) to relate characteristics of the anticancer lymphocytes and their parent populations to clinical outcomes following their use for treating patients, and 3) to help translate preclinical adoptive immunotherapy models, discovered in the Surgery Branch and elsewhere, into new clinical protocols. The core laboratory continues to process cells collected from cancer patients for a variety of uses. The collections serve as the precursor cells for generating the anticancer treatments described above. The products are routinely analyzed by investigators in the Surgery Branch immunotherapy program to help evaluate progress toward the goals of each immunotherapy clinical trial, as well as to address subsequent research questions that help identify changes needed in the clinical trials. In addition, the samples are used by Surgery Branch investigators for specific laboratory research projects that may translate into new patient therapies. These research projects include 1) transducing patients T cells with new genes whose products will provide better tumor recognition or otherwise enhance the cells anticancer functions, 2)evaluating the ability of infused anticancer lymphocytes to survive and function in the patient, 3) identifying new cancer antigens that may be recognized by patients anticancer cells, 4) identifying characteristics of infused anti-cancer T cells that relate to cancer regression as measured by standardized, objective criteria, 5) identifying common characteristics of patients with metastatic cancer who are more likely to respond ot adoptive cell therapy, 6) evaluating selected biological response modifiers tested in Surgery Branch clinical trials, and 7) extending adoptive cell therapy to additional types of metastatic cancer (e.g. cancers of the gastrointestinal tract and cancers induced by human papillomavirus). Finally, the Core Laboratory maintains and curates source documents, data, protocols, and expertise associated with cGMP manufacturing and clinical translation of cell therapies. Investigators within the Surgery Branch, intramural NCI laboratories, extramural regulatory agencies, industrial and academic collaborators, and other interested parties increasingly want access to these data, protocols and advice.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Scientific Cores Intramural Research (ZIC)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Dudley, Mark E; Gross, Colin A; Somerville, Robert P T et al. (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152-9
Morgan, Richard A; Chinnasamy, Nachimuthu; Abate-Daga, Daniel et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133-51
Rosenberg, Steven A; Dudley, Mark E (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-40
Johnson, Laura A; Morgan, Richard A; Dudley, Mark E et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-46
Ahmadzadeh, Mojgan; Johnson, Laura A; Heemskerk, Bianca et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-44
Yeh, Steven; Karne, Neel K; Kerkar, Sid P et al. (2009) Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116:981-989.e1
Klapper, Jacob A; Thomasian, Armen A; Smith, Douglas M et al. (2009) Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345:90-9
Tran, Khoi Q; Zhou, Juhua; Durflinger, Katherine H et al. (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31:742-51
Rosenberg, Steven A; Restifo, Nicholas P; Yang, James C et al. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308
Dudley, Mark E; Yang, James C; Sherry, Richard et al. (2008) Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. J Clin Oncol :

Showing the most recent 10 out of 13 publications